Here, the HCC1937 breast cancer cell line was treated with the BCL-XL:BIM-disrupting BH3-mimetic A1155463 and stained using either the HSBXB PRIMAB or the anti-BCL-XL antibody (Figure 3C). Here, BCL2L11 is linked to breast carcinoma.